Research Article
Meta-Analysis of the Therapeutic Effect of Shenqi Jiangtang Granule on Type 2 Diabetes Mellitus
Table 1
Principal characteristics of the studies included in the meta-analysis.
| Reference | Sample size (C/T) | Gender (male/female) | Age (range, mean) | Treatment method | Treatment cycle (week) | Measurement index |
| Zhang et al., 2019 [21] | 60/60 | T: 31/29 | C: 33/27 | T: 45–67 (57.13 ± 9.86) | C: 42–69 (57.46 ± 9.74) | T: SQJT + Metformin + Glimepiride | C: Metformin + Glimepiride | 12 | 1、2、3、4 | Sui 2019 [22] | 52/52 | T: 30/22 | C: 31/21 | T: 39–68 (54.31 ± 5.11) | C: 38–67 (53.25 ± 4.70) | T: SQJT + Metformin + Rosiglitazone | C: Metformin + Rosiglitazone | 12 | 1、2、4 | Liu and Gao, 2017 [23] | 20/20 | T: 23/14 | C: 10/10 | T: 41–65 (56.55 ± 7.17) | C: 42–65 (55.30 ± 7.36) | T: SQJT + Metformin | C: Metformin | 12 | 1、2、3、4 | Sun, 2017 [24] | 48/48 | T: 28/20 | C: 30/18 | T: 38–64 (56.27 ± 4.61) | C: 36–62 (54.15 ± 4.29) | T: SQJT + Metformin | C: Metformin | 8 | 1、2、3、4 | Wang, 2016 [25] | 69/69 | T: 43/26 | C: 41/28 | T: 25–65 (54.3 ± 3.2) | C: 26–65 (53.2 ± 3.4) | T: SQJT + Metformin + Insulin glargine | C: Metformin + Insulin glargine | 12 | 1、2、3、4 | Yang, 2017 [26] | 40/40 | T: 21/19 | C: 22/18 | T: 42–65 (55.8 ± 8.9) | C: 45–64 (55.4 ± 6.8) | T: SQJT + Metformin | C: Metformin | 24 | 2、3、4 | Chen, 2018 [27] | 52/52 | T: 32/20 | C: 31/21 | T: 26–63 (55.2 ± 3.5) | C: 27–60 (54.3 ± 3.7) | T: SQJT + Metformin | C: Metformin | 12 | 2、3、4 | Fan and Gao, 2014 [28] | 40/40 | T: 22/18 | C: 24/16 | T: 42–74 | C: 40–73 | T: SQJT + Metformin | C: Metformin | 12 | 1、2、3、4 | Zhang, 2019 [29] | 49/49 | T: 29/20 | C: 31/18 | T: 40–75 (59.18 ± 7.66) | C: 43–74 (60.27 ± 6.34) | T: SQJT + Metformin | C: Metformin | 12 | 3、4 | Song, 2018 [30] | 36/36 | T: 21/15 | C: 20/16 | T: 43–76 (59.12 ± 10.83) | C: 41–74 (58.94 ± 10.15) | T: SQJT + Liraglutide | C: Liraglutide | 12 | 1、2、3、4 | Li, 2015 [31] | 42/42 | T: 27/15 | C: 26/16 | T: 53–68 (63.1 ± 6.6) | C: 54–69 (62.8 ± 6.2) | T: SQJT + Repaglinide | C: Repaglinide | 4 | 1、2、3、4 | Wang, 2013 [32] | 42/42 | T: 26/16 | C: 27/15 | T: 35–66 (45.9 ± 7.4) | C: 33–63 (43.5 ± 5.2) | T: SQJT + Metformin | C: Metformin | 8 | 1、2、3、4 | Liu, 2018 [33] | 30/30 | T: 14/16 | C: 13/17 | T: 60–76 (67.2 ± 9.4) | C: 60–78 (66.8 ± 10.2) | T: SQJT + Metformin | C: Metformin | 12 | 2、3 |
|
|
Note. 1. Efficient; 2. FBG; 3. PBG; 4. HbA1c.
|